Explore Mazdutide dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Mazdutide (IBI362 / LY3305677) is a GLP-1 and glucagon receptor dual agonist based on the oxyntomodulin backbone, developed by Innovent and Eli Lilly and studied in the GLORY program for obesity and type 2 diabetes. Its glucagon arm adds an energy-expenditure component on top of GLP-1-driven appetite suppression. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting Mazdutide.
Mazdutide is an investigational once-weekly GLP-1/glucagon dual-agonist peptide, sourced in research for weight and metabolic studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.
Mazdutide is a synthetic analog of oxyntomodulin — the natural gut hormone that activates both the GLP-1 and glucagon receptors. The GLP-1 arm produces the standard incretin effects (glucose-dependent insulin secretion, slowed gastric emptying, appetite suppression). The glucagon arm increases resting energy expenditure and drives hepatic lipolysis, the hypothesized basis for the larger weight-loss and hepatic-fat-reduction signals seen in early trials versus pure GLP-1 agonists. Unlike retatrutide, mazdutide does not include a GIP receptor arm.
GLORY-1 (Ji et al., NEJM 2025) reported mean placebo-subtracted weight reduction of approximately 14.0% at 48 weeks on the 9mg arm in Chinese adults with obesity, the first published Phase 3 GLP-1/glucagon dual-agonist obesity readout. DREAMS-2 reported A1C reductions of ~1.6–2.1% at 9mg weekly in Chinese adults with T2D. A Phase 2 hepatic-fat substudy reported MRI-PDFF reductions consistent with the GLP-1/glucagon class signal. Lilly retains worldwide rights outside greater China and has not announced a U.S. registration program.
Mazdutide has a reported half-life of ~5 days (estimated), and the dose intervals researchers model most often fall around once weekly. A multi-day half-life supports once-weekly dosing, reaching steady state over roughly 4–5 weeks, so each dose lands on leftover from the previous week. It is catalogued under Weight Loss on WPA.
10 Mazdutide reconstitution calculations have been logged by the WPA community. The most common dose entered is 4mg (5 calculations). The most common bacteriostatic water volume is 3mL. The most popular vial size is 10mg (6 sessions). The most common dosing frequency is once weekly (2 logged protocols), followed by 2x/week (1).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.